ClinicalTrials.gg

Program

efgartigimod alfa

Also written as “Efgartigimod PH20 SC”, “efgartigimod PH20 SC” and “Efgartigimod IV”.

Its studies are mostly in Myasthenia Gravis · Purpura, Thrombocytopenic, Idiopathic · Pemphigus · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Graves Disease, led by argenx.

Furthest: phase 4, since Oct 7, 202448 company-led studies, 17 open or runningNext primary completion: Mar 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
argenx4817 open or runningphase 4since Oct 7, 2024Oct 20, 2016Mar 2027phase 3 · NCT04833894

Also a collaborator on its studies: iqvia-pty-ltd, Zai Lab and quintiles-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 35 studies since Oct 20, 2016.

  1. Apr 26, 2024Phase 3 study in Myasthenia GravisNCT06392386 · 12 planned · United States, Australia, Belgium and more
  2. Jul 31, 2024Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT06544499 · 69 planned · United States, Austria, Bulgaria and more
  3. Aug 14, 2024Phase 3 study in Myasthenia GravisNCT06558279 · 141 enrolled · United States, Australia, Austria and more
  4. Oct 7, 2024Phase 4 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06637072 · 23 enrolled · United States
  5. Oct 22, 2024Phase 2 study in Scleroderma, SystemicNCT06655155 · 87 enrolled · United States, Argentina, Belgium and more
  6. Nov 10, 2024Phase 3 study in Primary Sjogrens DiseaseNCT06684847 · 631 enrolled · United States, Argentina, Australia and more
  7. Mar 27, 2025Phase 4 study in New Onset Generalized Myasthenia Gravis (gMG)NCT06909214 · 30 planned · United States
  8. Sep 19, 2025Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT07194850 · 24 planned · France, Germany, Italy and more
  9. Dec 8, 2025Phase 2 study in Myasthenia GravisNCT07284420 · 70 planned · United States, Belgium, Germany and more
  10. Apr 30, 2026Phase 3 study in Graves DiseaseNCT07570316 · 230 planned · United States, Georgia, United Kingdom
  11. May 7, 2026Phase 2 study in Autoimmune Diseases of the Nervous SystemNCT07583641 · 170 planned · United States
  12. May 13, 2026Phase 3 study in Graves DiseaseNCT07596849 · 230 planned · Belgium, Bulgaria, Canada and more
  13. Jul 29, 2026Phase 2 study in Sjogrens DiseaseNCT07760818 · 75 planned
  14. Oct 19, 2026Primary completion moved from 2026-10-01 to 2027-10Date moved laterphase 3 · +12 months · NCT04812925

Ahead

  1. Mar 2027Primary completion: phase 2 study in Scleroderma, SystemicNCT06655155
  2. Mar 2027Primary completion: phase 3 study in Myasthenia GravisNCT04833894
  3. Apr 30, 2027Primary completion: phase 2 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT04280718
  4. Jul 2027Primary completion: phase 3 study in Primary Sjogrens DiseaseNCT06684847

TargetBeta

FCGRT →read by rule
“IgG receptor FcRn large subunit p51 antagonist”ChEMBL 37, by rule

Other programs on FCGRT

ProgramCompanyFurthest phaseStudies
rozanolixizumabruleUCBphase 423
nipocalimabruleJohnson & Johnsonphase 324
batoclimabruleimmunovant-sciences-gmbhphase 318

Studies

All 48 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07760818Sjogrens Disease2Not yet recruitingJul 28, 202875
NCT07596849Graves Disease · Belgium, Bulgaria, Canada and more3RecruitingJun 2028230
NCT07583641Autoimmune Diseases of the Nervous System · United States2Not yet recruitingJul 2030170
NCT07570316Graves Disease · United States, Georgia, United Kingdom3RecruitingJun 2028230
NCT07284420Myasthenia Gravis · United States, Belgium, Germany and more2RecruitingMar 7, 202870
NCT07194850Purpura, Thrombocytopenic, Idiopathic · France, Germany, Italy and more3RecruitingOct 202824
NCT06909214New Onset Generalized Myasthenia Gravis (gMG) · United States4RecruitingAug 202630
NCT06684847Primary Sjogrens Disease · United States, Argentina, Australia and more3Active, not recruitingJul 2027631
NCT06655155Scleroderma, Systemic · United States, Argentina, Belgium and more2Active, not recruitingMar 202787
NCT06637072Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States4CompletedFeb 19, 202623
NCT06558279Myasthenia Gravis · United States, Australia, Austria and more3Active, not recruitingJan 12, 2026141
NCT06544499Purpura, Thrombocytopenic, Idiopathic · United States, Austria, Bulgaria and more3RecruitingJun 202869
NCT06392386Myasthenia Gravis · United States, Australia, Belgium and more3RecruitingSep 202712
NCT06307626Graves Ophthalmopathy · United States, Austria, Bulgaria and more3TerminatedDec 15, 2025105
NCT06307613Graves Ophthalmopathy · United States, Australia, Belgium and more3TerminatedDec 15, 2025102
NCT06298552Myasthenia Gravis · United States, Belgium, Canada and more3Active, not recruitingJun 30, 2025119
NCT06203457Primary Sjögren's Syndrome · Belgium, Hungary, Poland2CompletedFeb 3, 202524
NCT05979441Myositis · United States, Argentina, Austria and more3By invitationSep 2028240
NCT05927415Renal Insufficiency · Germany1CompletedJun 12, 202433
NCT05918978Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome · United States2TerminatedAug 15, 202433
NCT05810961Glomerulonephritis, Membranous · China2TerminatedAug 5, 20248
NCT05817669Primary Sjögren's Syndrome · Belgium, Hungary, Netherlands and more2CompletedJan 29, 202434
NCT05810948Lupus Nephritis · China2CompletedJul 2, 202573
NCT05681481Pemphigoid, Bullous · United States, Australia, Bulgaria and more3TerminatedMar 20, 202564
NCT05633407Postural Orthostatic Tachycardia Syndrome · United States2CompletedApr 18, 202453
NCT05267600Pemphigoid, Bullous · United States, Australia, Bulgaria and more3CompletedSep 13, 202498
NCT05163834Healthy Volunteers · Netherlands1CompletedMar 8, 202236
NCT04980495Myasthenia Gravis · United States, Austria, Belgium and more3CompletedAug 24, 202369
NCT04833894Myasthenia Gravis · United States, Austria, Belgium and more3Active, not recruitingMar 202715
NCT04812925Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more3Active, not recruitingOct 2027173
NCT04818671Myasthenia Gravis · United States, Belgium, Czechia and more3CompletedDec 31, 2024184
NCT04735432Myasthenia Gravis · United States, Belgium, Georgia and more3CompletedNov 2, 2021110
NCT04687072Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more3CompletedOct 9, 2023207
NCT04598477Pemphigus · United States, Australia, Bulgaria and more3TerminatedMar 25, 2024183
NCT04598451Pemphigus · United States, Australia, Bulgaria and more3CompletedAug 22, 2023222
NCT04564066Healthy Volunteers · Netherlands1CompletedDec 24, 202054
NCT04280718Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Austria, Belgium and more2Active, not recruitingApr 30, 2027229
NCT04274452Purpura, Thrombocytopenic, Idiopathic3WithdrawnSep 1, 20210
NCT04225156Purpura, Thrombocytopenic, Idiopathic · United States, Austria, Belgium and more3CompletedMar 11, 2026101
NCT04188379Purpura, Thrombocytopenic, Idiopathic · United States, Austria, Belgium and more3CompletedFeb 3, 2022131
NCT04073589Healthy Volunteers · Netherlands1CompletedSep 26, 201933
NCT03770403Myasthenia Gravis · United States, Belgium, Canada and more3CompletedJun 23, 2022151
NCT03669588Myasthenia Gravis · United States, Belgium, Canada and more3CompletedApr 6, 2020167
NCT03457649Healthy Volunteers1CompletedNov 15, 201662
NCT03334084Bioavailability Study · Netherlands1CompletedSep 19, 201840
NCT03334058Pemphigus · Germany, Hungary, Israel and more2CompletedOct 28, 202034
NCT03102593Purpura, Thrombocytopenic, Idiopathic · Austria, Belgium, Czechia and more2CompletedApr 9, 201938
NCT02965573Myasthenia Gravis · United States, Belgium, Canada and more2CompletedOct 20, 201724

How it is read

Names in the registry

  • “Efgartigimod PH20 SC”, 12 entries
  • “efgartigimod PH20 SC”, 10 entries
  • “Efgartigimod IV”, 7 entries
  • “ARGX-113”, 7 entries
  • “Efgartigimod”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.